MedCity News June 15, 2022
The Court unanimously ruled it was unlawful for HHS to adjust reimbursement rates for hospitals participating in the federal 340B program without first conducting a survey.
In a case that has “immense economic consequences,” specifically $1.6 billion on the line, the U.S. Supreme Court unanimously ruled Wednesday that the Department of Health and Human Services acted unlawfully by reducing drug reimbursement rates for certain hospital groups without conducting a survey. The case revolves around the 340B drug pricing program.
The 340B federal program includes more than 2,500 hospitals that serve low-income and uninsured patients, and relies on subsidies to cover outpatient drug costs, but the Department of Health and Human Services stopped reimbursing 340B hospitals as much for...
Today's Sponsors
Today's Sponsor